Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma

Treiber, Gerhard; Wex, Thomas; Röcken, Christoph; Fostitsch, P.; Malfertheiner, P.

doi:10.1007/s00432-006-0118-4

Cited by 27 publications

(24 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The associations were independent of other clinicopathologic variables such as hepatitis etiologies, performance status, a-fetoprotein levels, and CLIP scores. Although previous studies have shown that blood IGF-1 levels are a prognostic marker for HCC (13,14,22), this is the first study showing the potential association between serum IGF-1 levels and the efficacy of systemic therapy for advanced HCC. The study was a retrospective analysis and did not include a control group of patients who did not receive therapy.…”

Section: Discussionmentioning

confidence: 78%

Serum Insulin-Like Growth Factor-1 Levels Predict Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy

Shao

Huang

Lin

et al. 2012

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Patients with liver cirrhosis or hepatocellular carcinoma (HCC) have decreased serum insulinlike growth factor (IGF)-1 levels. We evaluated whether IGF-1 levels were associated with the outcomes of patients with advanced HCC treated with systemic antiangiogenic therapy.Experimental Design: The study was based on patients with advanced HCC who were enrolled in two clinical trials evaluating first-line combination antiangiogenic therapy. Serum samples were collected before treatment and four to six weeks after the start of treatment. The levels of IGF-1, IGF-2, and IGF-binding protein-3 (IGFBP3) were analyzed for their associations with treatment outcomes.Results: A total of 83 patients were included in the study. Patients who had high (!the median level) baseline IGF-1 levels had significantly higher disease control rate (DCR) than patients who had low (

show abstract

Section: Discussionmentioning

confidence: 78%

Serum Insulin-Like Growth Factor-1 Levels Predict Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy

Shao

Huang

Lin

et al. 2012

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…In total, there were four tissue OS studies (Chow et al, 1997;Jeng et al, 2004a;Deli et al, 2005;Sheen et al, 2005), six tissue DFS studies (Jeng et al, 2004a;Sheen et al, 2005;Guo et al, 2006;Wada et al, 2006;Zhang et al, 2006;Ho et al, 2007), seven serum OS studies (Poon et al, 2001(Poon et al, , 2004a(Poon et al, , b, 2007Chao et al, 2003;Kim et al, 2004;Jeng et al, 2004b;Treiber et al, 2006), and five serum DFS studies (Poon et al, 2001(Poon et al, , 2007Chao et al, 2003;Jeng et al, 2004b;Treiber et al, 2006). Pooled HRs were then calculated for all groups.…”

Section: Summary Estimates Of Primary Studiesmentioning

confidence: 99%

“…Future directions could also emphasise the identification of optimal cut-points for high vs low VEGF levels, and determine the contribution of underlying cirrhosis to both VEGF levels and OS (Llovet et al, 2008). Although briefly discussed in one study (Treiber et al, 2006), additional investigations evaluating serial VEGF levels as a marker of disease progression or response to therapy would be a valuable addition to the literature. In the interim, this meta-analysis appears to initially support the hypothesis that high levels of VEGF are associated with a reduced probability of OS from HCC.…”

Section: Test For Heterogeneitymentioning

confidence: 99%

Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis

et al. 2009

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a highly vascular tumour that expresses vascular endothelial growth factor (VEGF). Various studies have evaluated the prognostic value of VEGF levels in HCC. Its overall test performance remains unclear, however. The aim was to perform a systematic review and meta-analysis of prognostic cohort studies evaluating the use of VEGF as a predictor of survival in patients with treated HCC. Eligible studies were identified through multiple search strategies. Studies were assessed for quality using the Newcastle–Ottawa Tool. Data were collected comparing disease-free and overall survival in patients with high VEGF levels as compared to those with low levels. Studies were pooled and summary hazard ratios were calculated. A total of 16 studies were included for meta-analysis (8 for tissue and 8 for serum). Methodological analysis indicated a trend for higher study quality with serum studies as compared to tissue-based investigations. Four distinct groups were pooled for analysis: tissue overall survival ( n =251), tissue disease-free survival ( n =413), serum overall survival ( n =579), and serum disease-free survival ( n =439). High tissue VEGF levels predicted poor overall (HR=2.15, 95% CI: 1.26–3.68) and disease-free (HR=1.69, 95% CI: 1.23–2.33) survival. Similarly, high serum VEGF levels predicted poor overall (HR=2.35, 95% CI: 1.80–3.07) and disease-free (HR=2.36, 95% CI 1.76–3.16) survival. A high degree of inter-study consistency was present in three of four groups analysed. Tissue and serum VEGF levels appear to have significant predictive ability for estimating overall survival in HCC and may be useful for defining prognosis in HCC.

show abstract

“…One could therefore say that the chances for the drug to work in receptor-negative patients are quite small. In previous papers, the percentage of receptor-positive patients was not defined (Treiber et al, 2006) or showed wide variability (Reynaert et al, 2004), even in relation to the type of receptor tested (Blaker et al, 2004).…”

Section: Sirmentioning

confidence: 98%

Octreotide and hepatocellular carcinoma

et al. 2007

View full text Add to dashboard Cite

show abstract

Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma

Cited by 27 publications

References 43 publications

Serum Insulin-Like Growth Factor-1 Levels Predict Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy

Serum Insulin-Like Growth Factor-1 Levels Predict Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy

Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis

Octreotide and hepatocellular carcinoma

Contact Info

Product

Resources

About